Drug Profile
Research programme: inducible phosphofrucotokinase-2 inhibitors - Ferring Pharmaceuticals
Alternative Names: iPFK-2 inhibitors - Ferring PharmaceuticalsLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Cytokine PharmaSciences
- Class Small molecules
- Mechanism of Action Phosphotransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Solid-tumours in USA
- 20 Oct 2011 Cytokine PharmaSciences has been acquired by Ferring Pharmaceuticals
- 01 Jun 2010 Preclinical trials in Solid tumours in USA (unspecified route)